Services
Lachman offers a full portfolio of capabilities to deliver measurable results for clients as they prevent and resolve compliance problems and develop new products for regulatory submission and approval by the FDA.
Learn More
About Lachman
Since 1978, Lachman Consultants’ multidisciplinary team of highly experienced FDA and industry experts has offered compliance, regulatory affairs, and technical services to clients around the world.
Learn More
Blog
Our blogs feature and report on the latest news and trends in the industry.
View the Blog

Latest Blogs

Me KASA es Su KASA – Long Overdue but Very Welcome

On Thursday (September 20th), the FDA held a meeting of the Pharmaceutical Science and Clinical Pharmacology Advisory Committee to discuss the Agency’s plans for implementation of the Knowledge‑aided Assessment and Structured Application program (KASA).  The FDA presented to the Advisory Committee two primary goals of the KASA program.  On the one hand, it is intended to make the review of the CMC section of NDAs,

Final ANDA Submission Guidance Published Today

The FDA has updated and finalized its guidance “ANDA Submissions – Content and Format”(here). The 38-page document goes into even more detail than the previous drafts and provides expanded explanations for certain sections and requirements for documents.

There is advice for each eCTD section and even an expanded Cover Sheet format suggested in Appendix A of the document. 

More Complete Response Letters – Good News or Bad News?

This morning I read Zach Brennan’s post on RAPS, titled FDA Smashes Record for Most ANDA Complete Responses Letters (CRLs) in One Year (here ).  In his piece, he wrote:

But the gap between this year and years past – 2,515 complete responses have been issued so far in 2018 vs.

FDA Takes Action on Opioids – Approves Final REMS

Yesterday the FDA announced the approval of a final REMS “governing the use of immediate-release opioid analgesic medications.”  And the FDA did it in a big way, approving some 437 supplements for the various immediate-release opioid products.  The FDA stated in its new release (here):

This new plan includes several measures to help better communicate the serious risks about the use of opioid pain medications to patients and health care professionals.  

About Lachman

Latest News

Visit Lachman Consultants at Booth 13/14 at AAM GRx + Biosims!

While you are attending the AAM GRx + Biosims meeting September 5-7, 2018 at the Hilton Baltimore, please be sure to visit Lachman Consultant Services at booth 13/14 and drop your business card for a chance to win an iPad 9.7 and Apple pen! As they say, you’ve got to be in it to win it!

Fran Zipp, CEO and President of LCS, to Moderate Panel at AAM GRx + Biosims Conference

On September 5, 2018, at 1:30 PM, Lachman Consultant Services’ CEO and President and CEO will be moderating a panel on Data Integrity at the AAM GRx + Biosims meeting. Ms. Zipp will be joined by Derek Glover (Head of Global Quality Systems and Compliance, Mylan Pharmaceuticals Inc.), Sarah Barkow, Ph.D. (Lead Consumer Safety Officer,